Postgraduate Program in Genetics and Biochemistry, Institute of Biotechnology (IBTEC), Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil.
Postgraduate Program in Cell Biology, Institute of Biomedical Sciences (ICBIM), Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil.
J Ethnopharmacol. 2020 Oct 28;261:113132. doi: 10.1016/j.jep.2020.113132. Epub 2020 Jul 14.
Plant materials are commonly used in traditional medicine in order to treat various diseases such as Diabetes mellitus. Some plants, such as Syzygium cumini, have the capability to act controlling oxidative stress and protein glycation besides their potential to decrease hyperglycemia and hyperlipidemia by the inhibition of the catalysis of digestive enzymes. The aim of this study was to evaluate the antioxidant and antiglicant activity of S. cumini leaves fractions, their capacity to inhibit hydrolases and lipase enzymes, as well as the cytotoxicity effects against erythrocytes and comparate these results with isolate quercetin flavonoid.
Ethnobotanical researches, carried out by academic studies at the Federal University of Uberlandia, led us to choose S. cumini as a potential plant for treatment of Diabetes mellitus. Fractions from ethanolic extract of S. cumini (hexane/Hex, dichloromethane/DCM, ethyl acetate/EtOAc, n-butanol/ButOH and water/HO) were used to evaluate their antioxidant (DPPH, ORAC and FRAP) and antiglycant (BSA/fructose, BSA/methylglyoxal and Arginine/Methylglyoxal) activity as well as the inhibitory potential against α-amylase, α-glucosidase and lipase. In addition, identification of the main bioactive compounds of S. cuimini leaves by HPLC-ESIMS/MS analysis was carried out.
Our results indicate that all fractions, for exception Hex, present noteworthy antioxidant activity, mainly in EtOAc and ButOH fractions (FRAP 1154.49 ± 67.37 and 1178.27 ± 21.26 μmol trolox eq g, respectively; ORAC 1224.63 ± 58.16 and 1313.53 ± 85.23 μmol trolox eq g, respectively; DPPH IC 15.7 ± 2.4 and 23.5 ± 2.7 μg mL, respectively). Regarding the antiglycant activity (BSA/fructose and Arginine/Methylglyoxal models), all fraction, for exception Hex, presented inhibition higher than 85%. All fractions were capable to inhibit 100% of α-amylase and the fractions DCM, EtOAc and ButOH inhibited α-glucosidase more than 50%. Regarding the lipase assay, DCM and Hex had the best activity (31.5 ± 14.3 and 44.3 ± 4.5 μg mL, respectively). Various biomolecules known as potent antioxidants were identified in these fractions, such as quercetin, kaempferol, luteolin and (Epi)catechin.
S. cumini fractions and quercetin presented promising antioxidant and antiglycation properties as well as the ability to inhibit digestive enzymes. This study presents new biological activities not yet described for S. cumini which provide new possibilities for further studies in order to assess the antidiabetic potential of S. cumini fractions especially EtOAc and ButOH.
植物材料常用于传统医学中,以治疗各种疾病,如糖尿病。一些植物,如 Syzygium cumini,除了通过抑制消化酶的催化作用降低高血糖和高血脂外,还有控制氧化应激和蛋白质糖化的能力。本研究旨在评估 S. cumini 叶部分的抗氧化和抗糖化活性,其抑制水解酶和脂肪酶的能力,以及对红细胞的细胞毒性作用,并将这些结果与分离出的槲皮素类黄酮进行比较。
民族植物学研究,由联邦大学的学术研究进行,使我们选择 S. cumini 作为治疗糖尿病的潜在植物。S. cumini 乙醇提取物的馏分(正己烷/Hex、二氯甲烷/DCM、乙酸乙酯/EtOAc、正丁醇/ButOH 和水/HO)用于评估其抗氧化(DPPH、ORAC 和 FRAP)和抗糖化(BSA/果糖、BSA/甲基乙二醛和精氨酸/甲基乙二醛)活性以及对α-淀粉酶、α-葡萄糖苷酶和脂肪酶的抑制潜力。此外,通过 HPLC-ESIMS/MS 分析对 S. cumini 叶的主要生物活性化合物进行了鉴定。
我们的结果表明,除了 Hex 之外,所有馏分都表现出显著的抗氧化活性,主要是在 EtOAc 和 ButOH 馏分中(FRAP 分别为 1154.49±67.37 和 1178.27±21.26 μmol trolox eq g;ORAC 分别为 1224.63±58.16 和 1313.53±85.23 μmol trolox eq g;DPPH IC 分别为 15.7±2.4 和 23.5±2.7 μg mL)。关于抗糖化活性(BSA/果糖和精氨酸/甲基乙二醛模型),所有馏分,除了 Hex 之外,都表现出高于 85%的抑制作用。所有馏分均能抑制 100%的α-淀粉酶,DCM、EtOAc 和 ButOH 馏分抑制α-葡萄糖苷酶的能力超过 50%。关于脂肪酶测定,DCM 和 Hex 具有最佳活性(分别为 31.5±14.3 和 44.3±4.5 μg mL)。在这些馏分中鉴定出了各种已知具有很强抗氧化能力的生物分子,如槲皮素、山奈酚、木犀草素和(Epi)儿茶素。
S. cumini 馏分和槲皮素表现出有希望的抗氧化和抗糖化特性,以及抑制消化酶的能力。本研究为 S. cumini 提供了尚未描述的新的生物学活性,为进一步评估 S. cumini 馏分特别是 EtOAc 和 ButOH 的抗糖尿病潜力提供了新的可能性。